LABT lakewood-amedex Biotherapeutics announces preclinical safety data supporting clinical dose selection for upcoming phase 2a trial of nu-

LABT lakewood-amedex Biotherapeutics announces preclinical safety data supporting clinical dose selection for upcoming phase 2a trial of nu-3 Gel Lakewood-amedex Biotherapeutics - nu-3 well tolerated at high doses with low systemic exposure in preclinical study - Finalizing preparation for phase 2a trial in infected diabetic foot ulcers